• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.

作者信息

Kogure Yoshihito, Ishii Yukira, Oki Masahide

机构信息

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

Department of Respiratory Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.

出版信息

J Thorac Oncol. 2019 Mar;14(3):e55-e57. doi: 10.1016/j.jtho.2018.11.025.

DOI:10.1016/j.jtho.2018.11.025
PMID:30782385
Abstract
摘要

相似文献

1
Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.帕博利珠单抗治疗晚期非小细胞肺癌患者时出现细胞因子释放综合征伴假性进展
J Thorac Oncol. 2019 Mar;14(3):e55-e57. doi: 10.1016/j.jtho.2018.11.025.
2
Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.一名鳞状细胞肺癌患者对帕博利珠单抗治疗成功应答后引发的气管食管瘘
J Thorac Oncol. 2019 Jul;14(7):e141-e143. doi: 10.1016/j.jtho.2019.02.013.
3
Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.接受化疗和帕博利珠单抗治疗的肺癌患者的组织学转化
J Thorac Oncol. 2017 Jun;12(6):e75-e76. doi: 10.1016/j.jtho.2017.02.006.
4
Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.帕博利珠单抗治疗晚期肺癌患者的真实世界经验
Am J Ther. 2019 Jul/Aug;26(4):e537-e538. doi: 10.1097/MJT.0000000000000762.
5
Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.帕博利珠单抗治疗晚期非小细胞肺癌后发生的致命性脑病。
J Neurooncol. 2019 Nov;145(2):399-402. doi: 10.1007/s11060-019-03289-7. Epub 2019 Sep 10.
6
Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer.一名非小细胞肺癌患者使用帕博利珠单抗后出现多发性硬化症。
J Neurol. 2019 Dec;266(12):3163-3166. doi: 10.1007/s00415-019-09562-z. Epub 2019 Oct 4.
7
Pembrolizumab and Severe Hypertriglyceridemia Requiring Apheresis: An Immune-Related Adverse Event.帕博利珠单抗与需进行血液分离术的严重高甘油三酯血症：一种免疫相关不良事件。
J Oncol Pract. 2019 Nov;15(11):613-614. doi: 10.1200/JOP.19.00245. Epub 2019 Oct 3.
8
Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.帕博利珠单抗诱发非小细胞肺癌患者发生伏格特-小柳-原田综合征
J Thorac Oncol. 2018 Oct;13(10):1606-1607. doi: 10.1016/j.jtho.2018.04.026. Epub 2018 May 3.
9
Susac's syndrome as an immune-related adverse event after pembrolizumab: a case report.帕博利珠单抗治疗后出现的免疫相关不良事件——苏萨克综合征：一例报告
J Neurol. 2020 Jan;267(1):282-284. doi: 10.1007/s00415-019-09587-4. Epub 2019 Nov 7.
10
Autoimmune-Related Primary Hypoparathyroidism Possibly Induced by the Administration of Pembrolizumab: A Case Report.帕博利珠单抗给药可能诱发的自身免疫性相关原发性甲状旁腺功能减退症：一例报告
J Oncol Pract. 2018 Jul;14(7):449-451. doi: 10.1200/JOP.18.00076. Epub 2018 Jun 15.

引用本文的文献

1
Hemophagocytic lymphohistiocytosis/cytokine release syndrome secondary to neoadjuvant pembrolizumab for triple-negative breast cancer: a case study.新辅助派姆单抗治疗三阴性乳腺癌继发噬血细胞性淋巴组织细胞增生症/细胞因子释放综合征：病例报告
Front Oncol. 2024 Jun 11;14:1394543. doi: 10.3389/fonc.2024.1394543. eCollection 2024.
2
Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients - A case report and review of the literature.癌症患者中免疫检查点抑制剂诱导的严重细胞因子释放综合征——病例报告及文献综述
Heliyon. 2024 Jan 10;10(2):e24380. doi: 10.1016/j.heliyon.2024.e24380. eCollection 2024 Jan 30.
3
Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
免疫检查点抑制剂的致命性系统性炎症综合征：病例报告和文献系统评价。
J Immunother Cancer. 2023 Mar;11(3). doi: 10.1136/jitc-2022-005841.
4
Cytokine release syndrome induced by pembrolizumab: A case report.帕博利珠单抗引起的细胞因子释放综合征：一例报告。
Medicine (Baltimore). 2022 Dec 9;101(49):e31998. doi: 10.1097/MD.0000000000031998.
5
Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.将连续评估法扩展到适应 I 期试验中的逐步加量给药。
Stat Med. 2022 Sep 10;41(20):3975-3990. doi: 10.1002/sim.9487. Epub 2022 Jun 5.
6
Cytokine release syndrome and successful response to pembrolizumab therapy in a patient with EGFR-mutated non-small-cell lung cancer: A case report.细胞因子释放综合征与 EGFR 突变型非小细胞肺癌患者对 pembrolizumab 治疗的成功反应：一例报告。
Thorac Cancer. 2022 May;13(9):1419-1422. doi: 10.1111/1759-7714.14390. Epub 2022 Apr 5.
7
Tumor-related cytokine release syndrome in a treatment-naïve patient with lung adenocarcinoma: A case report.一例未经治疗的肺腺癌患者发生肿瘤相关细胞因子释放综合征：病例报告
World J Clin Cases. 2022 Feb 16;10(5):1580-1585. doi: 10.12998/wjcc.v10.i5.1580.
8
Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report.帕博利珠单抗致转移性肺腺癌患者细胞因子释放综合征：1 例报告。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002855.
9
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.新辅助纳武利尤单抗治疗后发生迟发性细胞因子释放综合征：病例报告及文献复习。
Immunotherapy. 2021 Sep;13(13):1071-1078. doi: 10.2217/imt-2020-0329. Epub 2021 Jul 21.
10
Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.免疫检查点抑制剂治疗非小细胞肺癌引起的细胞因子释放综合征。
Intern Med. 2021 Nov 1;60(21):3459-3462. doi: 10.2169/internalmedicine.5922-20. Epub 2021 Mar 29.